Company Inhibrx, Inc.

Equities

INBX

US45720L1070

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
35.15 USD +0.23% Intraday chart for Inhibrx, Inc. +0.43% -7.50%

Business Summary

Inhibrx, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing a broad pipeline of novel biologic therapeutic candidates. The Company’s pipeline is focused on oncology and orphan diseases. Its clinical pipeline includes therapeutic candidates, such as INBRX-101, and INBRX-109. INBRX-101 is an engineered recombinant human alpha-1 antitrypsin fragment crystallizable (AAT-Fc) fusion protein therapeutic candidate that the Company is developing for the treatment of patients with Alpha-1 Antitrypsin Deficiency (AATD) and acute Graft-versus -host-disease (aGvHD). AATD is an inherited disease that causes an increased risk of developing pulmonary disease defined by progressive loss of lung tissue and function and is associated with decreased life expectancy. INBRX-109 is an engineered tetravalent therapeutic candidate targeting death-receptor 5 (DR5), a TNFRSF member, also known as tumor necrosis factor-related apoptosis-inducing ligand or TRAIL receptor 2.

Number of employees: 169

Sales per Business

USD in Million2022Weight2023Weight Delta
Biological Therapeutic Candidates
100.0 %
2 100.0 % 2 100.0 % -17.88%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
2 100.0 % 2 100.0 % -17.88%

Managers

Managers TitleAgeSince
Founder 45 10-03-31
Chief Executive Officer 57 10-03-31
Director of Finance/CFO 44 18-09-30
Chief Tech/Sci/R&D Officer - 21-12-31
Chief Tech/Sci/R&D Officer - 20-12-31
Chief Tech/Sci/R&D Officer 56 18-07-31
Chief Tech/Sci/R&D Officer - 19-12-31
Sales & Marketing - 23-01-31
General Counsel - 21-10-27
General Counsel - 18-12-31

Members of the board

Members of the board TitleAgeSince
Director/Board Member 60 18-03-31
Chief Executive Officer 57 10-03-31
Director/Board Member 64 20-05-31
Director/Board Member 55 18-03-31
Director/Board Member 56 21-10-27
Founder 45 10-03-31

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 47,392,447 33,760,797 ( 71.24 %) 0 71.24 %

Shareholders

NameEquities%Valuation
Viking Global Investors LP
15.09 %
7,150,826 15.09 % 262 M $
RA Capital Management LP
9.971 %
4,724,207 9.971 % 173 M $
Perceptive Advisors LLC
8.983 %
4,256,104 8.983 % 156 M $
Jon Kayyem
6.911 %
3,274,301 6.911 % 120 M $
Mark Lappe
6.428 %
3,045,654 6.428 % 112 M $
BlackRock Advisors LLC
5.436 %
2,575,672 5.436 % 94 M $
2,355,553 4.972 % 86 M $
Woodline Partners LP
4.894 %
2,318,576 4.894 % 85 M $
Vanguard Fiduciary Trust Co.
3.956 %
1,874,323 3.956 % 69 M $
TCG Crossover Management LLC
3.695 %
1,750,387 3.695 % 64 M $

Company contact information

Inhibrx, Inc.

11025 North Torrey Pines Road Suite 200

92037, La Jolla

+858 795 4220

http://www.inhibrx.com
address Inhibrx, Inc.(INBX)